CELLECTIS - ADR (CLLS)
US15117K1034 - ADR
Taking everything into account, CLLS scores 1 out of 10 in our fundamental rating. CLLS was compared to 588 industry peers in the Biotechnology industry. CLLS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CLLS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CLLS has reported negative net income.
In the past year CLLS has reported a negative cash flow from operations.
In the past 5 years CLLS always reported negative net income.
CLLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CLLS (-67.88%) is worse than 63.53% of its industry peers.
The Return On Equity of CLLS (-160.05%) is worse than 67.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.88% | ||
| ROE | -160.05% | ||
| ROIC | N/A |
ROA(3y)-29.26%
ROA(5y)-25.07%
ROE(3y)-57%
ROE(5y)-44.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CLLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLLS has more shares outstanding
CLLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CLLS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -2.60, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
CLLS has a Altman-Z score (-2.60) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.90 indicates that CLLS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.90, CLLS is doing worse than 76.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.6 |
ROIC/WACCN/A
WACC5.1%
2.3 Liquidity
A Current Ratio of 2.69 indicates that CLLS has no problem at all paying its short term obligations.
CLLS has a Current ratio of 2.69. This is in the lower half of the industry: CLLS underperforms 70.72% of its industry peers.
CLLS has a Quick Ratio of 2.69. This indicates that CLLS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CLLS (2.69) is worse than 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.69 | ||
| Quick Ratio | 2.69 |
3. Growth
3.1 Past
CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.86%, which is quite good.
CLLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.05%.
The Revenue has been decreasing by -5.27% on average over the past years.
EPS 1Y (TTM)14.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q57.51%
Revenue 1Y (TTM)-34.05%
Revenue growth 3Y3.82%
Revenue growth 5Y-5.27%
Revenue growth Q2Q-15.71%
3.2 Future
Based on estimates for the next years, CLLS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.88% on average per year.
CLLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.89% yearly.
EPS Next Y40.38%
EPS Next 2Y21.37%
EPS Next 3Y16.88%
EPS Next 5YN/A
Revenue Next Year-67.3%
Revenue Next 2Y-33.55%
Revenue Next 3Y5.51%
Revenue Next 5Y37.89%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLLS's earnings are expected to grow with 16.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.37%
EPS Next 3Y16.88%
5. Dividend
5.1 Amount
No dividends for CLLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CELLECTIS - ADR
NASDAQ:CLLS (4/26/2024, 7:00:00 PM)
After market: 2.55 +0.04 (+1.77%)2.5056
+0.02 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap180.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.88% | ||
| ROE | -160.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.69 | ||
| Quick Ratio | 2.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)14.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-34.05%
Revenue growth 3Y3.82%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y